Immune- and Nonimmune-Compartment-Specific Interferon Responses Are Critical Determinants of Herpes Simplex Virus-Induced Generalized Infections and Acute Liver Failure.
The interferon (IFN) response to viral pathogens is critical for host survival. In humans and mouse models, defects in IFN responses can result in lethal herpes simplex virus 1 (HSV-1) infections, usually from encephalitis. Although rare, HSV-1 can also cause fulminant hepatic failure, which is often fatal. Although herpes simplex encephalitis has been extensively studied, HSV-1 generalized infections and subsequent acute liver failure are less well understood. We previously demonstrated that IFN-αβγR-/-mice are exquisitely susceptible to liver infection following corneal infection with HSV-1. In this study, we used bone marrow chimeras of IFN-αβγR-/-(AG129) and wild-type (WT; 129SvEv) mice to probe the underlying IFN-dependent mechanisms that control HSV-1 pathogenesis. After infection, WT mice with either IFN-αβγR-/-or WT marrow exhibited comparable survival, while IFN-αβγR-/-mice with WT marrow had a significant survival advantage over their counterparts with IFN-αβγR-/-marrow. Furthermore, using bioluminescent imaging to maximize data acquisition, we showed that the transfer of IFN-competent hematopoietic cells controlled HSV-1 replication and damage in the livers of IFN-αβγR-/-mice. Consistent with this, the inability of IFN-αβγR-/-immune cells to control liver infection in IFN-αβγR-/-mice manifested as profoundly elevated aspartate transaminase (AST) and alanine transaminase (ALT) levels, indicative of severe liver damage. In contrast, IFN-αβγR-/-mice receiving WT marrow exhibited only modest elevations of AST and ALT levels. These studies indicate that IFN responsiveness of the immune system is a major determinant of viral tropism and damage during visceral HSV infections.


OBJECTIVE
Herpes simplex virus 1 (HSV-1) infection is an incurable viral infection with the most significant morbidity and mortality occurring in neonates and patients with compromised immune systems. Severe pathologies from HSV include the blindness-inducing herpetic stromal keratitis, highly debilitating and lethal herpes simplex encephalitis, and generalized infections that can lead to herpes simplex virus-induced acute liver failure. While immune compromise is a known factor, the precise mechanisms that lead to generalized HSV infections are unknown. In this study, we used and developed a mouse model system in combination with real-time bioluminescence imaging to demonstrate the relative importance of the immune and nonimmune compartments for containing viral spread and promoting host survival after corneal infection. Our results shed light on the pathogenesis of HSV infections that lead to generalized infection and acute liver failure.
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
Zachary M
ZM
Parker
Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
Tracy Jo
TJ
Pasieka
Charles River Laboratories, Hillsborough, North Carolina, USA.
George A
GA
Parker
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA david.a.leib@dartmouth.edu.
David A
DA
Leib
D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006561:Herpes Simplex / Q000209:etiology / Q000276:immunology* / Q000821:virology; D018259:Herpesvirus 1, Human / Q000276:immunology* / Q000472:pathogenicity* / Q000502:physiology; D006801:Humans; D016867:Immunocompromised Host; D007372:Interferons / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D016849:Keratitis, Herpetic / Q000209:etiology / Q000276:immunology / Q000821:virology; D008099:Liver / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D017114:Liver Failure, Acute / Q000209:etiology / Q000276:immunology* / Q000821:virology; D008297:Male; D051379:Mice; D057507:Mice, 129 Strain; D018345:Mice, Knockout; D011828:Radiation Chimera / Q000276:immunology; D017471:Receptors, Interferon / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D014779:Virus Replication / Q000276:immunology
D017471:Receptors, Interferon; D007372:Interferons
J Virol. 2002 Jul;76(14):7020-9
12072502
J Virol. 2002 Nov;76(22):11541-50
12388715
J Virol. 2002 Dec;76(23):12149-61
12414955
J Immunol. 2003 Mar 15;170(6):3331-6
12626593
Proc Soc Exp Biol Med. 1964 Mar;115:814-6
14155835
J Virol. 2003 Oct;77(20):11082-93
14512556
Methods Mol Biol. 2005;292:285-96
15507716
Clin Infect Dis. 1992 Jan;14(1):38-45
1571460
J Neurol. 2005 Mar;252(3):268-72
15761675
JAMA. 2006 Aug 23;296(8):964-73
16926356
Science. 2007 Sep 14;317(5844):1522-7
17872438
Liver Transpl. 2007 Oct;13(10):1428-34
17902129
BMJ Clin Evid. 2008 Jul 23;2008:null
19445742
Clin Transplant. 2009 Dec;23 Suppl 21:37-41
19930315
J Am Assoc Lab Anim Sci. 2010 Mar;49(2):202-6
20353696
J Virol. 2010 Oct;84(19):9685-94
20660188
Saudi J Kidney Dis Transpl. 2011 Jan;22(1):107-11
21196623
Nat Rev Immunol. 2011 Feb;11(2):143-54
21267015
J Pediatr. 2011 Oct;159(4):608-11
21529822
J Biomed Res. 2011 Mar;25(2):111-119
21709805
PLoS One. 2011;6(9):e24018
21915277
J Virol. 2011 Dec;85(24):12972-81
21994441
Neurochem Int. 2012 Jun;60(7):676-83
22100566
J Clin Invest. 2011 Dec;121(12):4889-902
22105173
J Immunol. 2012 Feb 1;188(3):1350-9
22210909
Curr Opin Virol. 2011 Dec;1(6):487-96
22347990
J Virol. 2012 Jul;86(14):7692-5
22553331
Prog Retin Eye Res. 2013 Jan;32:88-101
22944008
J Virol. 2013 Jul;87(13):7301-8
23596298
Virology. 2013 Sep;444(1-2):71-9
23777662
Nat Med. 2014 Jan;20(1):47-53
24362933
Front Immunol. 2014 Feb 06;5:15
24567732
Case Rep Crit Care. 2011;2011:138341
24826316
Neurology. 2014 Nov 18;83(21):1888-97
25339207
J Virol. 1989 Feb;63(2):759-68
2536101
J Immunol. 2015 Jan 1;194(1):379-87
25422507
Nat Rev Immunol. 2015 Feb;15(2):87-103
25614319
Biochemistry (Mosc). 2014 Dec;79(13):1635-52
25749169
J Gen Virol. 2015 Jul;96(Pt 7):1581-602
25794504
Mediators Inflamm. 2015;2015:593757
25918478
Future Virol. 2015 Jun;10(6):699-714
26213562
J Virol. 2015 Nov;89(21):11080-91
26311879
Immune Netw. 2015 Aug;15(4):191-8
26330805
Genes Immun. 2015 Dec;16(8):552-66
26513235
PLoS One. 2016 Feb 04;11(2):e0148564
26844767
J Immunol. 2016 Apr 1;196(7):3124-34
26903481
Adv Virus Res. 2016;94:53-80
26997590
Cell Mol Immunol. 2016 May;13(3):277-92
27041638
J Virol. 1995 Aug;69(8):4792-6
7609046
J Gen Virol. 1993 Sep;74 ( Pt 9):1859-69
8397283
Cell. 1996 Feb 9;84(3):431-42
8608597